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Abstract
Background: With the advance of microarray technology, several methods for gene classification and prognosis
have been already designed. However, under various denominations, some of these methods have similar
approaches. This study evaluates the influence of gene expression variance structure on the performance of
methods that describe the relationship between gene expression levels and a given phenotype through projection
of data onto discriminant axes.
Results: We compared Between-Group Analysis and Discriminant Analysis (with prior dimension reduction
through Partial Least Squares or Principal Components Analysis). A geometric approach showed that these two
methods are strongly related, but differ in the way they handle data structure. Yet, data structure helps
understanding the predictive efficiency of these methods. Three main structure situations may be identified.
When the clusters of points are clearly split, both methods perform equally well. When the clusters superpose,
both methods fail to give interesting predictions. In intermediate situations, the configuration of the clusters of
points has to be handled by the projection to improve prediction. For this, we recommend Discriminant Analysis.
Besides, an innovative way of simulation generated the three main structures by modelling different partitions of
the whole variance into within-group and between-group variances. These simulated datasets were used in
complement to some well-known public datasets to investigate the methods behaviour in a large diversity of
structure situations. To examine the structure of a dataset before analysis and preselect an a priori appropriate
method for its analysis, we proposed a two-graph preliminary visualization tool: plotting patients on the Between-
Group Analysis discriminant axis (x-axis) and on the first and the second within-group Principal Components
Analysis component (y-axis), respectively.
Conclusion: Discriminant Analysis outperformed Between-Group Analysis because it allows for the dataset
structure. An a priori knowledge of that structure may guide the choice of the analysis method. Simulated datasets
with known properties are valuable to assess and compare the performance of analysis methods, then
implementation on real datasets checks and validates the results. Thus, we warn against the use of unchallenging
datasets for method comparison, such as the Golub dataset, because their structure is such that any method
would be efficient.
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Background
In cancer research, microarray technology offers a new
tool for diagnosis of specific tumors or prognosis of sur-
vival. However, in microarray experiments, there are more
variables (genes) than samples (patients); if not taken
into account, this dimension problem leads to trivial
results with no statistical identifiability or biological sig-
nificance.
Among the methods proposed to overcome this problem,
some look for discriminant axes that best separate distinct
groups of patients according to specific characteristics.
These discriminant axes define a new space whose dimen-
sion is lower than that of the original gene space. The dis-
criminant axes are constructed as linear combinations of
genes; that is, each gene contributes to the construction of
the axes through a coefficient (weight) that depends on its
importance in discriminating the groups. Then, for predic-
tion purposes, new patients may be projected in this lower
space and assigned to the nearest group. This article
focuses on three types of discriminant analysis widely
used for prediction purposes: Principal Component Anal-
ysis (PCA) followed by Discriminant Analysis (DA), Par-
tial Least Squares followed by DA, and Between-Group
Analysis (BGA).
DA is proposed to define discriminant axes [1,2]. One
concern in DA is that it is limited by "high dimensional-
ity" and requires a preliminary dimension reduction step.
The classical approach to dimension reduction is PCA [3]
where components are such that they maximize the gene
expression variability across samples. Another approach
coming from chemometrics, the PLS method [4-8], selects
the components that maximize the covariance between
gene expression and phenotype response. To circumvent
this preliminary step within the context of microarray data
analysis, Culhane et al. [9] proposed the Between-Group
Analysis [10], because it can be directly used even when
the number of variables exceeds the number of samples.
A few recent publications were dedicated to comparisons
between projection methods within the context of micro-
array data analysis. Nguyen and Rocke compared PCA and
PLS as prior procedures to logistic discrimination or quad-
ratic discriminant analysis [11]. Boulesteix studied
PLS+DA in more detail [12]. Dai et al. proposed a new
comparison between PCA and PLS extended to a compar-
ison with the Sliced Inverse Regression (SIR) dimension
reduction method [13] as prior to logistic discrimination.
At the same time, Jeffery et al. [14] pointed out that the
variance structure of the dataset mostly influences the effi-
ciency and comparison of feature selection methods. No
similar work has been done to see whether the structure of
the variance of a given dataset may impact the efficiency
of the above-cited projection methods. Thus, bioinforma-
ticians may encountered difficulties in choosing the most
adapted method for a given dataset.
To solve these difficulties, we found it of major impor-
tance to extend the previous comparison studies by a
detailed look at the properties of DA -with previous PCA
or PLS- and BGA, to understand how some a priori knowl-
edge of the dataset structure may help choosing the most
appropriate method.
To achieve this goal, we used both simulated and public
well-know datasets in a complementary approach. As to
simulated datasets, the article presents a novel simulation
process to model various data structures, which leads to
different partitions of the whole variance into within-
group and between-group variances. A special attention is
given to the case where one discriminant axis separates
two groups; e.g., whenever a given phenotype classifies
the patients into two groups (for example, tumor vs. non-
tumor patients). The overall results are discussed to pro-
vide appropriate recommendations for more efficient
microarray analysis.
Methods
General analysis scheme
BGA and DA are based on the same principle: finding one
discriminant linear combination of genes that defines a
direction in p (gene space) along which the between-
group variance is maximized. The methodology of multi-
dimensional analysis provides an appropriate framework
[15]. Consider a (n * p) data array X that gives for each n
patients on rows the values of p gene expression levels.
Each column, the expression of one gene, is a vector of n
and each row, the set of gene expression for one patient of
the population, is a vector in p. The aim was to detect a
relationship between patients and genes and find a sub-
space that provides the best adjustment of the scatter plot.
This adjustment requires the definition of a metric in p,
given by a (p, p) positive symmetric matrix Q that defines
a scalar product and distances in p.
Introducing information about groups is necessary to find
a subspace in which the between-group variance is maxi-
mum. This may be reached through introduction of a
matrix of indicators Y, which enables group identification
to be incorporated in a new matrix Z. BGA and DA follow
the same general analysis scheme using this matrix Z and
specific choices for Q [16].
Definition of Z
Let the (n, k) matrix Y, containing k class indicators, define
a partition of the n patients. To maximize the between-
group variance, columns of X are projected on the sub-
space defined by the columns of Y. This projection is
obtained through the projection operator PY defined as: PYBMC Bioinformatics 2007, 8:90 http://www.biomedcentral.com/1471-2105/8/90
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= Y(tYY)-1(tY). Projecting patients on a class of k indicators
is equivalent to computing the mean expression of each
variable in class k. PYX is a (n, p) matrix where the varia-
bles for each patient are replaced by the corresponding
means of the class he belongs to. Actually, the rank of this
matrix is k - 1. With this choice of Z = PYX, maximizing the
variance of a linear combination of Z is equivalent to max-
imizing the between-group variance of X. BGA and DA
may be seen as a PCA of the mean matrix, each having its
own metric in p. As said above, BGA does not require a
preliminary dimension reduction before projecting
patients on the discriminant axis. However, DA requires
dimension reduction, which leads first to express patients
of X in a lower subspace. Xred contains the patients coordi-
nates in this reduced space. Zred is then a (n, p) matrix
where variables for each patient in the previously reduced
space are replaced by the corresponding means of the class
he belongs to.
Two methods are classically proposed to reduce dimen-
sion: normed PCA and PLS. They yield components that
are linear combinations of genes considered as the new
variables to analyze by DA [11]. Each of those compo-
nents includes all the initial variables weighted according
to their contribution to the effect caught by the compo-
nent. PCA aims at finding components that maximize the
projected variance of the data. In contrast, PLS looks
directly for components associated with the phenotype.
Only a subset of the first components is sufficient to catch
most of the data variance or covariance. The optimal
number of components was chosen by cross-validation, as
described by Boulesteix in the case of PLS+DA [12].
Choice of Q
Once Z chosen, BGA and DA derive from two distinct
choices for Q. In BGA, Q = Ip where Ip is the (p, p) identity
matrix. In DA, the metric Q  = (tXX)-1, so the metric
involves the total variance-covariance matrix for all
patients whatever their group. Another metric could be
the mean of the intra-group variances. It corresponds to
the so-called Linear Discriminant Analysis. The total vari-
ance being the sum of within-group and between-group
variances, there is a direct relationship between the two
methods. Whatever the metric, the assumption is that var-
iance-covariance matrices are similar in all groups. More-
over, in both cases, the metric involves an inversion of
(tXX), which requires not too strongly correlated varia-
bles. This is not typically the case in microarray studies
due to the huge number of variables, which calls for
dimension reduction.
Statistical solution
The general analysis applies to any pair (Z, Q). In BGA, the
pair is (Z, Ip) = (PYX, Ip); in DA, it is (Zred, (tXredXred)-1). The
general scheme aims at finding linear combinations Zα
maximizing ,  where  α is a (p, r) matrix. Those lin-
ear combinations define a subspace in which the variance
of Z is maximum. The single solution is given by singular
value decomposition of the matrix Q(tZ)Z. This matrix
can always be diagonalized and has p eigenvalues with r
non-zero ones λi, i = 1...r. The r corresponding eigenvec-
tors maximize   under Q-1-orthonormality con-
straint; they are defined in p, and called principal factors.
Columns of α contain these eigenvectors. By definition,
the αi are Q-1-normed. With this construction, linear com-
binations are uncorrelated.
In the particular case discussed here, where Z corresponds
to a mean table for two groups, there is only one discrimi-
nant axis, so r = 1. In the general case of k groups, r = k - 1.
Performance estimator
BGA and DA were compared using their predictive per-
formances; i.e., the proportion of correctly classified
patients.
The phenotype of a new patient was predicted according
to its position on the discriminant axis relative to the
threshold defined as:
In Equation (1),  G1,  G2, SDG1 and SDG2 are respec-
tively the means and standard deviations of the two
groups. This threshold was proposed by Culhane et al. [9]
for BGA and used here also for DA. It allows taking into
account the accuracy of the assignment, a greater weight
being given to the less scattered group.
Following the idea of Boulesteix [12], Leave-k-Out Cross-
Validation was used to obtain the proportion of correctly
classified patients. In each loop, the dataset was randomly
split so that k = 1/3 of the samples were left out and the
model derived using the 2/3 samples was applied to pre-
dict the class of the remaining samples. This operation
was repeated fifty times and a mean misclassification pro-
portion computed. With DA, the selection of the number
of components was included in the cross-validation proc-
ess. The mean misclassification proportion was deter-
mined for each number of components used as variables.
Finally, the number of components kept was the one for
which the misclassification proportion over the fifty runs
was minimal.
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The variability of the performance estimator (PE) was
measured somewhat differently with simulated and real
datasets. With simulated datasets and a given set of
parameters, the standard deviation of the PE was com-
puted over the fifty simulated datasets. This informs about
the variability stemming from the whole process used for
PLS+DA, PCA+DA, or BGA. The standard deviation of the
PE over the fifty cross-validation runs was computed for
each real dataset and for the optimal number of compo-
nents. This shows to which extent the choice of the split
that led to build the training sets may influence the pro-
portion of well-classified samples of the test set, with the
same number of components kept.
Implementation of methods
All computations were performed using R programming
language. The R code that enables to perform simulations
is available as additional file [see Additional file 1]. To
perform BGA, we used the made4 library [17]. To perform
DA with prior PLS or PCA, we relied on the plsgenomics
library [18].
Gene expression datasets
DLBCL
This dataset contains 7,129 expression levels on 58
patients with Diffuse Large B-Cell Lymphoma (DLBCL)
[19]. After preprocessing and use of a filter method, only
6,149 expression levels were kept. These patients are
divided into two subgroups depending on the 5-year sur-
vival outcome: 32 "cured" patients and 26 "fatal/refrac-
tory" patients. The data are available as .CEL files from the
Broad Institute website [20]. The gene expression values
were called using the Robust Multichip Average method
and data were quantile normalized using the Bioconduc-
tor package affy [21].
Prostate
This dataset provides 102 samples: 50 without and 52
with prostate tumors [22]. The data are available as .CEL
files from the Broad Institute website [23]. The gene
expression values were obtained as above.
ALL
This dataset includes 125 patients with Acute Lymphob-
lastic Leukemia [24]: 24 patients with and 101 without
multidrug resistance (MDR). The pre-processed data are
available in the ALL library in Bioconductor [21].
Leukaemia
This well-known dataset includes expression data on
7,129 genes from 72 tumor-mRNA samples [25]. These
acute leukaemia samples belong to two different subtypes
of leukaemia: 27 samples categorized as ALL (Acute Lym-
phoblastic Leukemia) and 45 categorized as AML (Acute
Myeloid Leukemia), which is the phenotype of interest.
Data are available in the golubEsets library in Bioconductor
[21]. The data were processed by making the min expres-
sion value 100 and the max expression value 16,000. The
log2 of the data was then used.
Results
The datasets used herein are either artificial data obtained
by an original simulation process or the above-cited two-
class public datasets.
Simulated datasets
Simulation process
Simulations were performed as a first step to understand
the influence of data structure on the results with DA and
BGA. An original simulation process was carried out to
evaluate the extent to which the above procedures were
able to retrieve the structure of a simple two-component
problem. We modeled different partitions of the whole
variance into within-group and between-group variances
using three parameters: i) the variance-covariance struc-
ture of each group; ii) the length of the vector joining the
barycenters of the two groups; and iii) the direction of this
vector, toward a high or a low within-group variance.
These three parameters result in several relative positions
and eccentricities of the scatter plots in the two-compo-
nent space.
The simulations started with the generation, in the com-
ponent space, of two groups with known within-group
variances. The maximum dimension of this component
space is n, the number of patients of the datasets. The
between-group difference was expressed in the two-com-
ponent space. In this space, variables were drawn from a
bivariate normal distribution N(µ, Σ) where Σ is a (2 * 2)
diagonal matrix with elements σ1 and σ2. µ depended on
the distance dist between the barycenters of the scatter
plots.
Thus, dist allowed controlling the between-group struc-
ture. The chosen ratio σ1/σ2 reflects eccentricity: the higher
it is, the higher is the eccentricity of the scatterplots; so,
this ratio allowed controlling the within-group structure.
The line joining the barycenters of the groups and the first
component axis forms an angle α. Figure 1 shows the geo-
metric meaning of these parameters. The n - 2 dimensions
left correspond to noise.
Next, patients were expressed in the n gene space. For
this, gene axes were derived from the component axes
through a chosen rotation, which masks more or less the
between-group structure present in the two-component
space.
The p - n genes left are random linear combinations of
these n genes.BMC Bioinformatics 2007, 8:90 http://www.biomedcentral.com/1471-2105/8/90
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The effect of dist and α
Table 1 shows prediction results for distances dist equal to
1, 3, and 5. The observed differences between DA and
BGA did not depend on the previous dimension reduc-
tion method, PCA or PLS. However, the number of com-
ponents kept was always greater (or equal) with PCA than
with PLS and, in some cases, this advantaged PCA+DA as
seen for dist = 1 and α = π/4, for example.
Whatever the method used and the value of α, prediction
was better as dist increased; that is, when the clusters of
points were the more distant. Moreover, the more distant
the barycenters were, the less the difference between DA
and BGA was.
Then, for a given distance, prediction results depended on
the value of α. The results with DA or BGA were the closest
for α = π/2 and α = 0: both inefficient with α = 0 and both
very efficient with α = π/2. This corresponded to situations
where the between-group direction was simulated on the
first or second component axis. For intermediate angles,
both methods were less good predictors, with neverthe-
less an advantage for DA.
The effect of eccentricity
Table 2 shows prediction results for several α and eccen-
tricities defined by ratio = σ1/σ2. A ratio of 1 corresponds
to a spherical cluster of points. As expected, the higher the
ratio was, the more advantageous was DA over BGA.
Moreover, except for α = 0, both methods performed gen-
erally better when eccentricity was high. With non-spher-
ical scatter plots, the best prediction was achieved with α
= π/2; that is, when the between-group direction was per-
pendicular to the within-group direction. When the ratio
decreased, DA and BGA got closer, the greatest difference
being with ratio = 10.
Table 3 shows the results when the main components of
the group variances were extremely different; that is, when
the directions of the principal component of the two clus-
ters of points were perpendicular. In that case, DA and
BGA had similar results whatever α. Note that PCA was
less efficient; in fact, the between-group part was low in
the whole variance structure.
As a general remark, it may be noted that the standard
deviation of the performance estimator over the fifty sim-
View of the component space relative to the simulations Figure 1
View of the component space relative to the simulations. The cluster of points of each of the two groups was plotted 
in the two-component space. The scatter plots barycenters are distant by dist. The direction of the between-group variance 
draws an angle α with the first component.BMC Bioinformatics 2007, 8:90 http://www.biomedcentral.com/1471-2105/8/90
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ulated datasets was low whatever the variance partition
examined.
Comparable results of simulations were obtained when
differences were expressed in two- or three-component
spaces.
Real datasets
The public datasets were chosen to cover the main situa-
tions encountered in practice.
To begin the analysis of a new dataset, we suggest to first
have a look at its structure to visualize the relative role of
the within-group and between-group variances for distin-
guishing the two groups of patients. For this, we propose
two graphs obtained by plotting patients on the BGA dis-
criminant axis (x-axis) and on the first and the second
within-group PCA component (y-axis), respectively. The
greatest part of the between-group variance is given by the
most differential genes, while the other genes tend to
mask this between-group structure. For this prior exami-
nation of the data structure, we used only the fifty genes
with the highest t-test statistics.
Figures 2 to 5 show the plots that correspond to each data-
set. In the case of the DLBCL dataset (Figure 2), the clus-
ters of points were not discrete; the cluster relative to the
cured patients was even found within the "fatal/refrac-
tory" cluster. This suggests that the dataset has no obvious
between-group structure. Moreover, the main compo-
nents of the variances in each group were very different.
In the case of the prostate dataset (Figure 3), the distinc-
tion between non-tumor and tumor samples was found
along both between-groups and the first within-group
directions.
In the case of the ALL dataset (Figure 4), the distinction
between patients with or without multidrug resistance
(MDR) was found along the first within-group direction.
Table 2: Proportion of well-classified patients according to ratio, which reflects eccentricity
α = π/2 α = π/3 α = π/4 α = π/6 α = 0
ratio = 10
PLS+DA 0.82(0.05)//2 0.81(0.03)//2 0.76(0.03)//2 0.71(0.04)//2 0.59(0.04)//2
PCA+DA 0.85(0.05)//3 0.81(0.04)//3 0.77(0.05)//3 0.73(0.05)//3 0.59(0.04)//3
BGA 0.76(0.05) 0.75(0.04) 0.66(0.03) 0.67(0.04) 0.58(0.04)
ratio = 2
PLS+DA 0.68(0.05)//1 0.65(0.04)//1 0.65(0.05)//1 0.65(0.05)//2 0.63(0.05)//1
PCA+DA 0.69(0.05)//3 0.65(0.04)//3 0.67(0.04)//2 0.65(0.04)//2 0.63(0.04)//2
BGA 0.67(0.06) 0.62(0.04) 0.64(0.05) 0.65(.04) 0.62(0.05)
ratio = 1
PLS+DA 0.60(0.05)//2 0.62(0.05)//1 0.64(0.05)//2 0.62(0.05)//1 0.61(0.05)//1
PCA+DA 0.63(0.04)//3 0.63(0.04)//2 0.63(0.05)//2 0.64(0.05)//2 0.63(0.05)//2
BGA 0.61(0.05) 0.62(0.05) 0.61(0.05) 0.61(0.05) 0.60(0.05)
Mean (Standard deviation)//Median of the optimal number of components over over fifty datasets simulated with a distance between the 
barycenters dist = 2. PLS: Partial Least Squares – PCA: Principal Components Analysis – DA: Discriminant Analysis.
Table 1: Proportion of well-classified patients according to dist, the distance between the barycenters of the two groups
α = π/2 α = π/3 α = π/4 α = π/6 α = 0
dist = 1
PLS+DA 0.69(0.05)//2 0.69(0.06)//2 0.64(0.06)//2 0.60(0.06)//2 0.59(0.05)//1
PCA+DA 0.69(0.04)//3 0.70(0.05)//2 0.66(0.06)//3 0.60(0.05)//3 0.58(0.06)//1
BGA 0.63(0.05) 0.61(0.06) 0.55(0.06) 0.57(0.05) 0.58(0.05)
dist = 3
PLS+DA 0.93(0.04)//2 0.91(0.03)//2 0.86(0.03)//2 0.71(0.03)//2 0.69(0.06)//1
PCA+DA 0.94(0.04)//2 0.91(0.03)//2 0.85(0.04)//3 0.71(0.04)//3 0.69(0.05)//2
BGA 0.90(0.04) 0.79(0.03) 0.73(0.03) 0.70(0.03) 0.67(0.06)
dist = 5
PLS+DA 0.98(0.04)//2 0.97(0.01)//2 0.97(0.02)//2 0.84(0.03)//2 0.79(0.04)//1
PCA+DA 0.99(0.01)//3 0.98(0.01)//2 0.97(0.02)//2 0.83(0.03)//2 0.79(0.04)//2
BGA 0.91(0.04) 0.91(0.01) 0.86(0.03) 0.82(0.03) 0.79(0.04)
Mean (Standard deviation)//Median of the optimal number of components over fifty datasets simulated with eccentricity such that ratio = 10. PLS: 
Partial Least Squares – PCA: Principal Components Analysis – DA: Discriminant Analysis.BMC Bioinformatics 2007, 8:90 http://www.biomedcentral.com/1471-2105/8/90
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At last, in the case of the leukaemia dataset (Figure 5), the
barycenters were only separated by the between-group
direction. This indicates that the between-group direction
was perpendicular to the within-group direction.
So, these four datasets reflect various structures of vari-
ance; these structures may be associated to simulated
datasets to see how their main characteristics explain the
predictive behaviour of the methods. Table 4 shows the
proportion of well-classified patients obtained over the
fifty cross-validation runs with the optimal number of
components. The standard deviation of the performance
estimator over the fifty cross-validation runs was low. This
standard deviation shows the variability of the perform-
ance estimator between cross-validation runs. Here, it
indicated that the way of splitting patients into training
and test sets within each run did not affect the results.
As expected in the light of the structure visualization, the
proportions of well-classified samples for the DLBCL were
low whatever the method used, BGA being the less effi-
cient. In fact, DA needed 12 PLS components or 13 PCA
components to optimize prediction while, with only one
component, BGA is not able to catch more information
given by the within-group structure. This corresponded in
the simulated datasets to a low value of dist.
As to the prostate dataset, the plots led to compare this
dataset to the case where α is intermediate between 0 and
π/2. Thus, we could foretell that the results would be
improved in comparison with those of the DLBCL dataset,
and that DA will be more advantageous. Indeed, this was
confirmed with the proportions of well-classified sam-
ples: DA was more efficient in predicting non-tumor or
tumor samples. It seemed that the high number of com-
ponents kept for the first dimension reduction allowed
getting more information than a single projection in BGA.
The ALL dataset corresponded to simulating α near to 0;
none of the methods was really adapted to such a config-
uration. Actually, no methods was sufficiently efficient.
PCA as first dimension reduction method was not able to
catch information. On the contrary, with 10 PLS compo-
nents, DA overcame BGA.
As to the leukaemia dataset, it recalled the simulated case
with  α  =  π/2, which is the one that allowed the best
results. This was confirmed in Table 4, where the three
methods were particularly efficient in distinguishing ALL
and AML patients. The prediction results obtained with
BGA and DA were very similar. With dimension reduc-
tion, one PLS component and five PCA components were
needed to optimize prediction. The results with PCA sug-
gested that the between-group variance took the largest
part of the total variance.
Further figures are provided as additional files showing
the structure of other well-known datasets: DLBCL vs FL
[see Additional file 2], Colon (normal vs tumor samples)
[see Additional file 3], Myeloma (With vs without lytic
lesions) [see Additional file 4], ALL1 (B-Cell vs T-Cell ori-
gin) [see Additional file 5], ALL2 (Relapse vs no relapse)
[see Additional file 6], ALL3 (With vs without t(9;22)
translocation) [see Additional file 7]. The corresponding
proportions of well-classified patients obtained over the
fifty cross-validation runs with the optimal number of
components are provided in additional file 8 [see Addi-
tional file 8].
Discussion
Results from both simulated and real datasets showed that
the structure of a dataset influences to a large extent the
efficiency of the methods that use projection on discrimi-
nant axes.
In testing a new method, simulated and real datasets play
complementary roles. Simulation of data with known
properties is useful to study the influence of the dataset
characteristics and the performance of a given method,
and could be considered as a practical guide to under-
stand results from real situations. For choosing an analysis
method to discriminate two groups of patients, we think
it is necessary to have a prior examination of the structure
of the data to analyze. This will enable an informed choice
between the available methods.
We propose here a new simulation approach that allows
exploring known structures with control through several
parameters. Nguyen [26] proposed to simulate datasets to
Table 3: Proportion of well-classified patients with a high eccentricity (ratio = 10) in one group and a low eccentricity (ratio = 0.1) in 
the other group
DLBCL Prostate ALL Leukaemia
PLS+DA 0.51(0.14)//12 0.97(0.06)//10 0.73(0.05)//10 0.97(0.03)//1
PCA+DA 0.49(0.09)//13 0.96(0.07)//9 0.57(0.08)//1 0.95(0.04)//5
BGA 0.43(0.10) 0.70(0.09) 0.60(0.06) 0.98(0.03)
Mean (Standard deviation)//Median of the optimal number of components over fifty datasets simulated with dist = 2. PLS: Partial Least Squares – 
PCA: Principal Components Analysis – DA: Discriminant Analysis.BMC Bioinformatics 2007, 8:90 http://www.biomedcentral.com/1471-2105/8/90
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Prostate dataset Figure 3
Prostate dataset. Projection of the 102 patients from the 
prostate dataset (50 without and 52 with tumor) on the dis-
criminant axis obtained with BGA (x-axis), along their coor-
dinates on the first (on the top) and the second (on the 
bottom) within-group PCA component (y-axis), respectively. 
For a better legibility, the groups were labeled 0 (for non-
tumor prostate samples) and 1 (for tumor prostate samples). 
Only the 50 most differential genes among 12625 were used 
for these graphs.
DLBCL dataset Figure 2
DLBCL dataset. Projection of the 58 patients from the 
DLBCL dataset (32 "cured" and 26 "fatal/refractory") on the 
discriminant axis obtained with BGA (x-axis), along their 
coordinates on the first (on the top) and the second (on the 
bottom) within-group PCA component (y-axis), respectively. 
For a better legibility, the groups were labeled 0 (for "cured" 
patients) and 1 (for "fatal/refractory" patients). Only the 50 
most differential genes among 6149 were used for these 
graphs.BMC Bioinformatics 2007, 8:90 http://www.biomedcentral.com/1471-2105/8/90
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Leukemia dataset Figure 5
Leukemia dataset. Projection of the 72 patients from the 
leukaemia dataset (25 Acute Lymphoblastic Leukemia -ALL- 
and 47 Acute Myeloide Leukemia -AML-) on the discriminant 
axis obtained with BGA (x-axis), along their coordinates on 
the first (on the top) and the second (on the bottom) within-
group PCA component (y-axis), respectively. For a better 
legibility, the groups were labeled 0 (for AML patients) and 1 
(for ALL patients). Only the 50 most differential genes among 
7129 were used for these graphs.
ALL dataset Figure 4
ALL dataset. Projection of the 125 patients from the ALL 
dataset (24 with and 101 without Multi Drug Resistance -
MDR-) on the discriminant axis obtained with BGA (x-axis), 
along their coordinates on the first (on the top) and the sec-
ond (on the bottom) within-group PCA component (y-axis), 
respectively. For a better legibility, the groups were labeled 0 
(for patients with MDR) and 1 (for patients without MDR). 
Only the 50 most differential genes among 12625 were used 
for these graphs.BMC Bioinformatics 2007, 8:90 http://www.biomedcentral.com/1471-2105/8/90
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compare the performance of PCA and PLS as prior proce-
dure before logistic discrimination. However, his method
of simulation did not allow a discussion on the influence
of the data structure. Our simulations allow generating
different structures of different degrees of complexity and
assessing the impact of three parameters: the distance
between the clusters, the eccentricity of these clusters, and
their relative positions in a two-dimensional component
space. The major source of complexity in real microarray
datasets is the existence of regulation networks. In our
simulations, this may be described by a component with
a very large variance; that is, a large eccentricity. This cor-
responds usually to a common effect on all the genes. A
high variance on one component corresponds also to a
cluster of highly correlated genes. Whether a network of
genes exists or not would determine the relative impor-
tance of the other components with respect to the first
one. Nevertheless, we are aware that our simulations have
limits. Therefore, a compromise has to be found between
the uncontrolled nature of real datasets and the controlled
nature of simulated datasets as research tools. This will be
the object of future works.
The use of real datasets to prove the superiority of any
method should be considered with caution. For example,
the leukaemia dataset from Golub, very often used to
demonstrate the efficiency of a new method, may not be
used for that purpose because of its very strong between-
group structure. This structure is such that we expect the
groups to be distinguished whatever the method used
(e.g., BGA that simply joins the barycenters of the groups).
We believe that, in such situations, the good performance
of a particular method does not only inform on its ability
to discriminate between groups. If the structure of the
dataset had been previously examined before its analysis,
for example with the graphical tool we propose, this data-
set would not have been chosen to validate new predic-
tion methods. Thus, bioinformaticians should be
cautious in choosing the datasets to use for method com-
parisons. The proposed visualization tool helps in choos-
ing the dataset, by having an idea of its structure. The
prostate or ALL datasets for example may be appropriate
for that purpose.
Besides, the structure of a given dataset may depend on
the type of disease. In diagnosis, some pathophysiological
entities may be already clearly identified; if their origin is
a metabolic activation, they will induce different proc-
esses that will be easy to distinguish (e.g., ALL vs. AML).
However, differentiating patients with or without multid-
rug resistance may be even more difficult because no
pathophysiological entities are involved. In prognosis,
distinguishing good from bad prognosis patients would
be more difficult because they often share the same patho-
physiological characteristics.
Three main configurations of the data structure may be
identified. When the clusters of points are quite distinct
the between-group difference is so obvious that the
within-group structure will have no impact; BGA and DA
will give good prediction results. The simple method that
consists in drawing an axis between the barycenters is suf-
ficient. In fact, the way of projecting patients on the discri-
minant axis does not come into consideration. On the
opposite, there are situations in which both methods are
inappropriate. This corresponds to superposed clusters of
points obtained in plotting the within-group versus the
between-group coordinates. In other situations, we
believe that DA is more advantageous than BGA because
it allows taking into account the partition of the total var-
iance into between and within variances. However, in case
the variances of the two groups are not the same, the total
variance will not reflect the variance in each group, so
there will be no advantage of favoring DA over BGA.
Moreover, keeping more than one component in the first
dimension reduction step using PLS or PCA is a way to
capture more information than the single projection in
BGA, particularly with PLS. This is illustrated with the ALL
dataset; by keeping ten PLS components, DA outperforms
BGA to a large extent (respectively 0.97% and 0.70% of
well-classified patients). These observations illustrate the
fact that the first PLS component and the BGA discrimi-
nant axis are identical. This was demonstrated by Barker
and Rayens [27], and by Boulesteix [12]. Thus, using PLS
with one component followed by DA gives a final compo-
nent that is collinear to that of PLS alone, and also to the
BGA axis. This is illustrated with the leukaemia dataset,
Table 4: Proportion of well-classified patients with real datasets
PLS+DA PCA+DA BGA
DLBCL 0.51(0.14)//12 0.49(0.09)//13 0.43(0.10)
Prostate 0.97(0.06)//10 0.96(0.07)//9 0.70(0.09)
ALL 0.73(0.05)//10 0.57(0.08)//1 0.60(0.06)
Leukaemia 0.97(0.03)//1 0.95(0.04)//5 0.98(0.03)
Mean (Standard deviation) over the fifty cross-validation runs for the optimal number of component (indicated after //). Results were obtained with 
the DLBCL, the prostate, the ALL, and the leukaemia datasets. PLS: Partial Least Squares – PCA: Principal Components Analysis – DA: Discriminant 
Analysis.BMC Bioinformatics 2007, 8:90 http://www.biomedcentral.com/1471-2105/8/90
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where PLS+DA and BGA give equivalent results (respec-
tively 0.97% and 0.98% of well-classified patients). How-
ever, in simulations, PLS+DA seemed to yield, on average,
slightly better results than BGA. In fact, due to random
sampling, some simulated datasets needed more than one
component to optimize prediction because dimensions
other than those simulated may be informative by chance
alone. Note that in case of a spherical cluster of points, a
second PLS component will not capture more informa-
tion than the first one and both methods will be equally
efficient.
Overall, DA becomes advantageous when the structure of
the variance is such that the way of projecting patients on
the discriminant axis needs to come into consideration.
This leads to conclude that DA is the most suitable
method; it provides better or at least equivalent results in
a diversity of datasets because it ensures that the within-
group variance will be taken into account, when relevant.
The diversity of real datasets encountered confirms the
fact that, unlike DA, BGA is unable to deal with too com-
plex data structures. The only advantage of BGA is its ease
of use and interpretation: a single projection enables to go
from the original variable space to a one-dimension axis
on which inter-group variance is maximum.
This axis is also a direct linear combination of genes where
a high coefficient means that the gene is important to clas-
sify the patients into one of the groups. With DA, the sam-
ples are first expressed in a component space, which
makes interpretation more difficult.
BGA and DA used with more than two groups provide k -
1 discriminant axes, which enables each of the k groups to
be separated from the k - 1 others. By plotting these groups
in successive two-dimensional graphs, the structure
assessment described here may be applied to each of the
two-dimension spaces so obtained.
Conclusion
We have established here that the two methods -BGA and
DA with prior PCA or PLS- are based on very similar
approaches. Efficient use of these projection methods
requires some a priori knowledge of the structure of the
clusters of points. We found that three main structure sit-
uations may be identified. When the clusters of points are
clearly split, both methods will perform equally well and
it becomes futile to prove the superiority of one method
over the other using datasets previously shown of simple
structure. When the clusters of points superpose, both
methods will fail to yield interesting predictions. In such
a case, there is no linear way to separate groups, leading to
the use of non linear methods. In intermediate situations,
the structure of the clusters of points has to be taken into
account by the projection to improve prediction, which
imposes the use of DA. So, we recommend the use of Dis-
criminant Analysis to take into account more diverse data-
set structures.
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Additional material
Additional file 1
R codes used to generate simulated datasets. This simulation process 
generates several datasets structures by modelling different partitions of 
the whole variance into within-group and between-group variances.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-8-90-S1.pdf]
Additional file 2
DLBCL vs FL dataset. Projection of 58 patients with Diffuse Large B-Cell 
Lymphoma and 19 patients with Follicular Lymphoma on the discrimi-
nant axis obtained with BGA (x-axis), along their coordinates on the first 
(on the top) and the second (on the bottom) within-group PCA compo-
nent (y-axis), respectively. For a better legibility, the groups were labeled 
0 (for FL-patients) and 1 (for DLBCL-patients). Only the 50 most differ-
ential genes among 7129 were used for these graphs. The data are avail-
able from the Broad Institute website [20].
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-8-90-S2.jpeg]
Additional file 3
Colon dataset. Projection of 22 normal controls and 40 tumor samples 
on the discriminant axis obtained with BGA (x-axis), along their coordi-
nates on the first (on the top) and the second (on the bottom) within-
group PCA component (y-axis), respectively. For a better legibility, the 
groups were labeled 0 (normal controls) and 1 (for tumor samples). Only 
the 50 most differential genes among 2000 were used for these graphs. 
The data are available in the ColonCA library in Bioconductor [21].
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-8-90-S3.jpeg]
Additional file 4
Myeloma dataset. Projection of 36 patients with and 137 patients with-
out lytic lesions on the discriminant axis obtained with BGA (x-axis), 
along their coordinates on the first (on the top) and the second (on the 
bottom) within-group PCA component (y-axis), respectively. For a better 
legibility, the groups were labeled 0 (lytic lesions) and 1 (without lytic 
lesions). Only the 50 most differential genes among 12625 were used for 
these graphs. Data can be download from Gene Expression Omnibus [28] 
(accession number GDS531).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-8-90-S4.jpeg]BMC Bioinformatics 2007, 8:90 http://www.biomedcentral.com/1471-2105/8/90
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Additional file 5
ALL1 dataset. Projection of 95 Acute Lymphoblastic Leukaemia (ALL) 
patients with B-Cell and 33 with T-Cell origin on the discriminant axis 
obtained with BGA (x-axis), along their coordinates on the first (on the 
top) and the second (on the bottom) within-group PCA component (y-
axis), respectively. For a better legibility, the groups were labeled 0 (B-
Cell) and 1 (T-Cell). Only the 50 most differential genes among 12625 
were used for these graphs. The data are available in the GOstats library 
in Bioconductor [21].
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-8-90-S5.jpeg]
Additional file 6
ALL2 dataset. Projection of 65 ALL patients that did and 35 that did not 
relapse on the discriminant axis obtained with BGA (x-axis), along their 
coordinates on the first (on the top) and the second (on the bottom) 
within-group PCA component (y-axis), respectively. For a better legibility, 
the groups were labeled 0 (no relapse) and 1 (relapse). Only the 50 most 
differential genes among 12625 were used for these graphs. The data are 
available in the GOstats library in Bioconductor [21].
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-8-90-S6.jpeg]
Additional file 7
ALL3 dataset. Projection of 26 ALL-patients with and 67 ALL-patients 
without the t(9;22) translocation on the discriminant axis obtained with 
BGA (x-axis), along their coordinates on the first (on the top) and the sec-
ond (on the bottom) within-group PCA component (y-axis), respectively. 
For a better legibility, the groups were labeled 0 (without t(9;22)) and 1 
(with t(9;22)). Only the 50 most differential genes among 12625 were 
used for these graphs. The data are available in the GOstats library in 
Bioconductor [21].
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-8-90-S7.jpeg]
Additional file 8
Proportion of well-classified patients for complementary two-class real 
datasets. Mean (Standard Deviation) over the fifty cross-validation runs 
for the optimal number of component (indicated after //). The table shows 
results for the following datasets: DLBCL vs FL, Colon, Myeloma, ALL1, 
ALL2, and ALL3.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-8-90-S8.pdf]